# Abbott and Alere amend acquisition terms, drop lawsuits

Abbott and Alere announced amended terms for Abbott's pending acquisition of Alere. Abbott will pay $51 per share for an expected equity value of $5.3 billion, down from $5.8 billion. The companies have dismissed lawsuits against each other and extended the regulatory approval deadline to September 30, 2017.

- Type: Acquisition
- Announced: 2017-04-23
- Where: United States
- Value: $5.30B
- Status: announced
- Products: point-of-care testing devices
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Abbott Laboratories](https://endata.com/companies/20171.md) (acquirer)
- [Alere](https://endata.com/companies/23753.md) (target)

## Sources

- [healio.com](https://www.healio.com/news/cardiology/20170421/terms-of-abbott-acquisition-of-alere-changed-lawsuits-dropped), 2017-04-23: "Abbott and Alere announced that the terms for Abbott’s pending acquisition of Alere have been amended and the companies have ceased litigation against each other."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.